Generic Name and Formulations:
Sotalol HCl 80mg, 120mg, 160mg, 240mg; scored tabs.
Indications for BETAPACE:
Documented life-threatening ventricular arrhythmias.
Initiate and titrate up in hospital with appropriate monitoring. Initially 80mg twice daily. Increase at 3-day intervals to usual maintenance 120–160mg twice daily; usual range 160–320mg/day divided in 2 or 3 doses (refractory patients may need 480–640mg/day). Renal impairment (CrCl <60mL/min): prolong dosing interval (see full labeling).
Sinus bradycardia. 2nd or 3rd degree AV block unless paced. Long QT syndromes. Cardiogenic shock. Uncontrolled CHF (patients with NYHA Class IV may not tolerate beta-blockade; titrate slowly and give full support if attempting to use sotalol in these patients). Asthma.
Do not substitute for Betapace AF. Increased arrhythmia risk in females, sustained ventricular tachycardia, electrolyte disorders (esp. hypokalemia, hypomagnesemia), excessive QT prolongation, history of cardiomegaly, CHF, renal impairment, and high doses. Correct electrolyte imbalances and withdraw other antiarrhythmics before starting. Baseline QTc interval >500msec; consider lowering dose or discontinuing if QTc interval exceeds 550msec. Sick sinus syndrome. Bronchospastic disease. CHF. Left ventricular dysfunction. Recent acute MI. Diabetes. Acid-base imbalance. Hyperthyroidism. History of anaphylaxis. Surgery. Avoid abrupt cessation (withdraw over 1–2 weeks if possible, monitor for angina and acute coronary insufficiency). Pregnancy (Cat.B). Nursing mothers: not recommended.
Class II and III antiarrhythmic.
Class IA antiarrhythmics (eg, disopyramide, quinidine, procainamide), Class III antiarrhythmics (eg, amiodarone), or other drugs that prolong QT interval (eg, some phenothiazines, cisapride, bepridil, tricyclic antidepressants, macrolides): not recommended. Caution with Class IB and IC antiarrhythmics. Additive conduction abnormalities and hypotension with digitalis, β-blockers, calcium channel blockers. Hypotension, bradycardia with reserpine, guanethidine, other catecholamine-depleting drugs. Increased rebound hypertension when withdrawing clonidine. Diuretics (monitor electrolytes). Antagonizes albuterol, other β-agonists. Monitor antidiabetic agents. May block epinephrine. Avoid within 2 hours of aluminum- or magnesium-containing antacids.
Dyspnea, fatigue, nervousness, bradycardia, chest pain, palpitation, asthenia, light-headedness, GI disturbances; sleep, respiratory, vascular or visual disorders; edema, headache, ECG abnormalities, hypotension, new or exacerbated arrhythmias (eg, torsade de pointes), syncope.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Short Forms of Parent General Behavior Inventory Reliable at Identifying Youth Mood Symptoms
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Unexpected Effect of Substance Use Disorders on Recovery From Bipolar Depression
- Republican Opposition to Obamacare: What's Done, What's to Come
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Integrating Treatments for Opioid Use Disorder and Infectious Diseases